Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)

BACKGROUND: Telavancin—a lipoglycopeptide antibacterial agent active against Gram-positive pathogens including methicillin-sensitive and -resistant Staphylococcus aureus (MRSA)—is approved in the USA for once-daily intravenous use. This registry study captured patient characteristics, prescribing pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Bressler, Adam M., Hassoun, Ali A., Saravolatz, Louis D., Ravenna, Valerie, Barnes, Chris N., Castaneda-Ruiz, Bibiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879699/
https://www.ncbi.nlm.nih.gov/pubmed/31696440
http://dx.doi.org/10.1007/s40801-019-00165-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879699/
https://www.ncbi.nlm.nih.gov/pubmed/31696440
http://dx.doi.org/10.1007/s40801-019-00165-8

Ejemplares similares